Literature DB >> 32145273

The management of glucocorticoid deficiency: Current and future perspectives.

Rosemary Dineen1, Julie Martin-Grace1, Christopher J Thompson1, Mark Sherlock2.   

Abstract

Glucocorticoid deficiency is the clinical state characterised by inadequate cortisol production. It may occur due to the primary failure of the adrenal cortex or to lack of stimulation of the adrenal cortex by adrenocorticotropic hormone. The aim of treatment of glucocorticoid deficiency is to mimic the normal physiological secretion of cortisol, in order to normalise quality of life and reverse pathological sequelae. However, the diurnal rhythm of cortisol secretion is difficult to reproduce with exogenous glucocorticoid therapy. There is wide inter- and intra-individual variability of in the dynamics of physiological glucocorticoid secretion, and glucocorticoid preparations that are currently available cannot reproduce physiological profiles. In addition, there are no reliable biomarkers to determine the adequacy of treatment. The treatment of acute glucocorticoid deficiency/ adrenal crisis involves prompt recognition and administration of parenteral hydrocortisone, rehydration, and management of electrolyte abnormalities. In the management of chronic glucocorticoid deficiency, the prevention of adrenal crisis must be balanced with avoidance of the long-term adverse effects of over-replacement. This requires close collaboration with the patient, for whom education and empowerment in the management of glucocorticoid deficiency, and the prevention of crises, are crucial.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adrenal insufficiency; Cortisol; Hydrocortisone; Hypothalamic-pituitaryadrenal axis

Mesh:

Substances:

Year:  2020        PMID: 32145273     DOI: 10.1016/j.cca.2020.03.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  1 in total

Review 1.  Drug-induced comorbidities in patients with sarcoidosis.

Authors:  Marjolein Drent; Naomi T Jessurun; Petal A Wijnen; Otto Bekers; Aalt Bast
Journal:  Curr Opin Pulm Med       Date:  2022-07-18       Impact factor: 2.868

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.